Follow-up Study to Monitor the Efficacy and Safety of the Occlutech® mVSD Cases
NCT ID: NCT05329350
Last Updated: 2026-02-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
50 participants
OBSERVATIONAL
2022-03-03
2029-10-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The objectives of the study are:
* To confirm the efficacy of Occlutech mVSD in patients requiring transcatheter occlusion (closure) of muscular ventricular septal defects.
* To confirm the safety of Occlutech mVSD in patients requiring transcatheter occlusion (closure) of muscular ventricular septal defects.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Multicenter, International, Follow-up Study to Monitor the Efficacy and Safety of the Occlutech® PmVSD Occluder in Patients With Perimembranous Ventricular Septal Defects
NCT04034498
An International Multicenter Study on Transcatheter Device Closure of Perimembranous Ventricular Septal Defects
NCT06823635
Closure of Muscular Ventricular Septal Defects (VSDs) With the AMPLATZER Muscular VSD (MuVSD) Occluder - Post Approval Study
NCT00647387
Closure of Muscular Ventricular Septal Defects With The AMPLATZER™ Muscular VSD Occluder
NCT00583791
Implantation of a Permanent Interatrial Shunt to Reduce Left Atrial Filling Pressures Following MitraClip
NCT04729933
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Safety and efficacy of implanted devices are assessed by echocardiography, vital signs, laboratory tests, and ECGs on Day 1 (within 48 hours post-procedure), follow-up 1 (between Day 30 and Day 60), follow-up 2 at 6 months (from Day 61 until 6 months), follow-up 3 at 1 year (from 6 months until 1 year), and follow-up 4 at 3 years (from 1 year until 3 years).
* Patients will be screened to determine eligibility for the registry based on inclusion/exclusion criteria, through their medical history, demographics, vital signs, clinical laboratory tests, performance of a 12 lead electrocardiogram (ECG) and echocardiography data.
* Participants are treated according to the instructions-for-use (IFU) of the device and according to clinical routine.
* Procedures are performed at sites having appropriate laboratory support and adequately trained imaging personnel. The procedure is performed by physicians with experience in a wide range of interventional cardiology and structural heart disease, including transcatheter patent ductus arteriosus, atrial septal defect, and ventricular septal defect (VSD) closures.
Recruitment will be open until 50 Patients have been enrolled. The primary safety endpoint is defined as the incidence of Serious Adverse Device Effects (SADEs) including procedure-related death, procedure-related stroke, ischemic stroke, systemic embolism, severe hemolysis, complete heart block requiring pacemaker implantation or device explanation, new onset of severe tricuspid regurgitation (TR), new the onset of severe aortic regurgitation (AR), severe right-left ventricular outflow obstruction (RVOTO-LVOTO), device embolization, cardiac tamponade, infective endocarditis, or vascular complications requiring open heart surgery up to 1 year after the mVSD closure procedure.
The primary efficacy endpoints will include data obtained 1 year after the mVSD closure procedure for successful implantation of the device with a proper closure of the mVSD (defined as the reduction in muscular ventricular septal shunt to trivial or no shunt at all, as assessed by echocardiography pre- vs post-implantation).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
muscular ventricular septal defects
patients with muscular ventricular septal defects
Occlutech muscular ventricular septal defect (mVSD) Occluder
Percutaneous, transcatheter (catheter-based) non-surgical closure of a muscular ventricular septal defect (mVSD) using the Occlutech mVSD Occluder. The device is a self-expandable nitinol wire-mesh occluder with two retention discs connected by a flexible waist and incorporates polyester/PET patches to support defect occlusion and tissue ingrowth. Implantation is performed by experienced operators in a specialized cath lab according to the IFU and local routine; device sizing/selection is guided by imaging (e.g., transthoracic echocardiography, angiography, fluoroscopy). The system is deployed using compatible Occlutech delivery accessories (e.g., Occlutech Pistol Pusher and Occlutech Delivery Set \[ODS v1 or ODS III\], as applicable).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Occlutech muscular ventricular septal defect (mVSD) Occluder
Percutaneous, transcatheter (catheter-based) non-surgical closure of a muscular ventricular septal defect (mVSD) using the Occlutech mVSD Occluder. The device is a self-expandable nitinol wire-mesh occluder with two retention discs connected by a flexible waist and incorporates polyester/PET patches to support defect occlusion and tissue ingrowth. Implantation is performed by experienced operators in a specialized cath lab according to the IFU and local routine; device sizing/selection is guided by imaging (e.g., transthoracic echocardiography, angiography, fluoroscopy). The system is deployed using compatible Occlutech delivery accessories (e.g., Occlutech Pistol Pusher and Occlutech Delivery Set \[ODS v1 or ODS III\], as applicable).
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Any age
* Male or female.
* Patients understand the nature of the study and provide their informed consent to participation.
* Patients willing and able to attend the follow-up visits and procedures foreseen by study CIP.
Contraindication
* Hemodynamically relevant VSD shunt
* Congestive heart insufficiency
* Recurrent respiratory infections
* Failure to thrive.
* Significant left ventricle (LV) enlargement
* Significant left atrium (LA) enlargement
* Other clinical indication
Exclusion Criteria
⦁Active bacterial infections
* Active infection at the time of implantation
* Allergy to antiplatelet or anticoagulant therapy
* Allergy to nickel and/or titanium and/or nickel/titanium-based materials
* Any type of serious infection 1 month before the procedure
* The aortic rim of less than 2 mm
* Demonstrated intracardiac thrombi on echocardiography
* Malignancy where life expectancy is less than 3 years
* mVSD diameter \> 20 mm
* Perimembranous VSD
Post-MI VSD
* Recent myocardial infarction or a surgical bypass operation in the last 30 days
* Sepsis (local or generalized)
* Septal thickness \> 7 mm in the area of the Occluder placement
3 Months
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Occlutech International AB
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Children's Health Ireland
Dublin, , Ireland
İzmir Şehir Hastanesi
Izmir, Bayraklı, Turkey (Türkiye)
Eskişehir Osmangazi Üniversite Hastanesi
Eskişehir, Odunpazarı, Turkey (Türkiye)
Dicle Üniversitesi Tıp Fakültesi Hastanesi
Diyarbakır, Sur, Turkey (Türkiye)
Gaziantep Unıversıty Hospital
Gaziantep, Şehitkamil, Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Claire Josephine Karungi Betz, SC
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Occ2016_07
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.